Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/ 212Bi generator

• Published in: Nuclear medicine and biology Vol. 32; no. 7; pp. 741 - 747
• Main Authors: Su, Fu-Min, Beaumier, Paul, Axworthy, Don, Atcher, Robert, Fritzberg, Alan
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2005
• Subjects: Animals; Biotin - analogs & derivatives; Biotin - pharmacokinetics; Biotin - therapeutic use; Bismuth - pharmacokinetics; Bismuth - therapeutic use; Bismuth-212; Cell Line, Tumor; Colorectal Neoplasms - metabolism; Colorectal Neoplasms - radiotherapy; Drug Delivery Systems - methods; Female; Humans; In situ radionuclide generator; Lead Radioisotopes - pharmacokinetics; Lead Radioisotopes - therapeutic use; Lead-212; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Organ Specificity; Organometallic Compounds - pharmacokinetics; Organometallic Compounds - therapeutic use; Pre-targeting; Radioimmunotherapy; Radioimmunotherapy - methods; Radioisotopes - pharmacokinetics; Radioisotopes - therapeutic use; Radionuclide therapy; Radiopharmaceuticals - pharmacokinetics; Radiopharmaceuticals - therapeutic use; Rats; Rats, Sprague-Dawley; Tissue Distribution; Tumor; Pre-targeting; Radioimmunotherapy

Pretargeting is the concept that combines optimal delivery of the antibody and rapid capture and elimination of the radioactivity. In this study, we evaluated the potential of antibody pretargeting to enable the tumor-targeting 212Pb for in vivo generation of 212Bi for α particle radiotherapy. The 2...